Documents
Resources
Learning Center
Upload
Plans & pricing Sign in
Sign Out
Get this document free

IBPL signs agreement with Kotak Private Equity Group

VIEWS: 4 PAGES: 2

									                                                         Plot No. 423/P/A/GIDC, Sarkhej-Bavla Highway
                                                        Moraiya, Tal: Sanand, Ahmedabad – 382 210 INDIA
                                                         Tel: (02717) – 660100/660101; Fax: (02717) – 251189




   IBPL signs agreement with Kotak Private Equity Group
Ahmedabad, October 9, 2007: Intas Biopharmaceuticals Limited (IBPL) has signed an
agreement with Kotak Private Equity Group (KPEG) leading towards an investment of $
10 Million in IBPL as equity. The FIPB application is a part of the due process for the
same investment. Intas Biopharmaceuticals Limited will utilize this investment for capital
expansion to enhance its R&D & manufacturing capabilities based in Gujarat. India.

Speaking on the development, Shri Mani Iyer, Director IBPL, said, “With new products
in the pipeline and planned efforts to launch these products on domestic and
international front, the strategic investment of KPEG in IBPL will give a significant boost
to our efforts in registering and commercializing products in many regulated markets.
The company is looking to double its R&D strength by the end of this year. After
completion of its expansion, IBPL will be capable to undertake 10-12 new projects at a
time, which will speed up the product development cycle. IBPL, which has already
invested close to Rs 100 crore at its facility, plans to pump in additional Rs 150 crore
over the next 4-5 years.” IBPL is looking to developing innovative platform technologies
in bio-therapeutics space, identify partnering opportunities, in-licensable IPs; and to
build up Novel Drug Delivery System

After receiving quality certification from European regulatory agency, Evaluation of
Medicinal Products (EMEA), IBPL is extensively eying European market where it has
initiated clinical trial activity for its product Neukine. Apart from the regulated market of
Europe, company has focussed its effort to strengthen its alliance with North American
technology companies with whom IBPL has entered into Research & Development
collaboration, which offers unique opportunity to IBPL to commercialize the technology
as well as the product.

The EU-GMP certification has opened new avenues for the company to explore
existing/new technologies and processes.




For further information, Contact:                                                                         1
Mr. Siddharth J. Baad, Corporate Communications
0091-2717-660205; siddharth.baad@intasbiopharma.co.in
                                                         Plot No. 423/P/A/GIDC, Sarkhej-Bavla Highway
                                                        Moraiya, Tal: Sanand, Ahmedabad – 382 210 INDIA
                                                         Tel: (02717) – 660100/660101; Fax: (02717) – 251189




About Intas Biopharmaceuticals Limited
IBPL has fully integrated biopharmaceutical operations at Ahmedabad, Gujarat. Since
the launch of biotechnology operations in May 2000, R&D and manufacturing of
biopharmaceutical products with a special focus on Oncology (Cancer) are major thrust
areas for the company. The manufacturing facility is well equipped for production of
fermentation as well as cell culture derived bulk drugs and finished products in pre-filled
syringes and vials. Indus Biotherapeutics, a 100% subsidiary of IBPL, is a dedicated
biopharmaceutical Contract Research Organization that concentrates on research and
development of novel targets as well as bio-generics. Indus’ expertise lies in process
and product development, analytical method development, bio-chemical immunological
analysis, process validation, scale-up and technology transfer to manufacturing scale.




For further information, Contact:                                                                         2
Mr. Siddharth J. Baad, Corporate Communications
0091-2717-660205; siddharth.baad@intasbiopharma.co.in

								
To top